Murine radiation-induced acute myeloid leukaemia (AML) is characterized by loss of one copy of chromosome 2. Previously, we positioned the critical haematopoietic-specific transcription factor PU.1 within a minimally deleted region. We now report a high frequency (>65%) of missense mutation at codon 235 in the DNAbinding Ets domain of PU.1 in murine AML. Earlier studies, outside the context of malignancy, determined that conversion of arginine 235 (R235) to any other amino-acid residue leads to ablation of DNA-binding function and loss of expression of downstream targets. We show that mutation of R235 does not lead to protein loss, and occurs specifically in those AMLs showing loss of one copy of PU.1 (P ¼ 0.001, Fisher's exact test). PU.1 mutations were not found in the coding region, UTRs or promoter of human therapy-related AMLs. Potentially regulatory elements upstream of PU.1 were located but no mutations found. In conclusion, we have identified the cause of murine radiation-induced AML and have shown that loss of one copy of PU.1, as a consequence of flanking radiation-sensitive fragile domains on chromosome 2, and subsequent R235 conversion are highly specific to this mouse model. Such a mechanism does not operate, or is extremely rare, in human AML.
PU.1 is a member of the ETS family of transcription factors and is essential for the development of both myeloid (macrophages and neutrophils) and lymphoid lineages (B-and T-lymphocytes) (Moreau-Gachelin et al., 1989; Klemsz et al., 1990; Tenen et al., 1997) . Gene expression is confined to mast cells and haematopoietic cells such as multipotent interleukin-3 progenitor cells, B cells, macrophages and neutrophils Hromas et al., 1993; Chen et al., 1995) . The PU.1 protein has been shown in vitro to interact with a number of myeloid-and lymphoid-specific promoters and enhancers, and is known to regulate the expression of numerous critical myeloid genes including integrin, alpha M (CD11b), interferon regulatory factor 4 (IRF4), the macrophage colony-stimulating factor (CSF1) receptor, the granulocyte-macrophage colony-stimulating factor (CSF2) and the granulocyte colony-stimulating factor (CSF3) receptor (Pahl et al., 1993; Zhang et al., 1994; Hohaus et al., 1995; Smith et al., 1996; Anderson et al., 1999) . The complete block on myeloid lineage development in PU.1 À/À mice highlights the key role played by the PU.1 transcription factor in the development of a mature haematopoietic system (Scott et al., 1994; McKercher et al., 1996 McKercher et al., , 2003 .
A mouse model of radiation-induced acute myeloid leukaemia (AML) has been used to localize a putative tumour suppressor gene to a 1.0 cM region homologous to the human chromosomal segment 11p11-p12 (Silver et al., 1999) . PU.1 (Sfpi1) maps to this chromosomal region and the majority (>90%) of induced AMLs were found to have lost one copy of the gene. One cell line (Mlp3) out of five lines derived from induced leukaemias had lost both copies abrogating PU.1 expression. PU.1 was found to be transcribed in all the F1 AMLs and cell lines tested with the exception of the Mlp3 cell line, which was null (Silver et al., 1999) .
Heterozygous PU.1 mutations have been reported in human AML (7%, 9/126; Mueller et al., 2002) . The 10 mutant alleles identified affected the Ets DNA-binding domain, the Pest domain and the transactivation domain. Biallelic mutations were rare (2/9) as the majority of AMLs with mutations retained the wildtype allele. However, the frequency with which PU.1 mutations arise in AML remains contentious, because multiple subsequent studies have failed to identify a single mutation (Lamandin et al., 2002; Vegesna et al., 2002; Dohner et al., 2003; Ley et al., 2003; Mueller et al., 2003) . As the AMLs analysed were primarily de novo (the study of Vegesna et al. and Lamandin et al. excluded therapy(t)-related AML), it is possible that mutation of PU.1 may arise more frequently in secondary or tAML than de novo AML; tAML is a known consequence of radio-and chemotherapy (Leone et al., 1999; Smith, 2003) .
Using a large number of murine AMLs induced by Xirradiation, we have undertaken direct sequencing of the PU.1 gene. In murine AMLs (n ¼ 45) induced by Xirradiation in F1 hybrids (CBA/H Â C57BL/Lia and C3H/He Â C57BL/6J) and the C3H/He inbred mouse (Seki et al., 1991; Silver et al., 1999) , we identified a high frequency (67%, 30/45) of missense mutation leading to replacement of the arginine 235 (R235) residue within the Ets domain of PU.1 with cysteine (C; 49%, 22/45), serine (S; 16%, 7/45) or histidine (H; 2%, 1/45; 
Amino-acid residues are arginine (R), cysteine (C), serine (S) and histidine (H). Normal DNA included matched normal brain DNA (n ¼ 23) and DNA from parents of F1's (n ¼ 8). F1 AMLs induced in CBA/H Â C57BL/Lia (n ¼ 27), including those referred to in Silver et al. (1999) , were checked for LOH for the PU.1 chromosomal segment using flanking microsatellites D2mit15, D2mit383, D2mit272 and D2mit44, and fluorescencebased genotyping on an ABI3100 sequencer Sussex, UK) made up to 25 ml using demineralized water. The PCR reaction conditions: 951C for 10 min, one cycle; 35 cycles of 951C for 35 s, annealing at optimum temperature for 35 s, and 721C for 35 s; and 721C for 10 min, one cycle. Sequencing reaction conditions: 10 ml of the purified PCR product (Qiaquick PCR purification kits (Qiagen)), 1 ml of forward primer or reverse primer, 1 ml of demineralized water and 8 ml of 1 : 2 BDT. Sequencing analysis: 6 ml of the purified product (Dyex2.1 purification kit (Qiagen)) and 6 ml of Hi-Dit formamide. The sequencing was performed on the ABI Prism 3100 (ABI Applied Biosystems, Warrington, UK). The sequence was confirmed using the reverse reaction. (b) Western blot of PU.1 protein in mouse ML cell lines. Mouse ML cell lines established from murine radiationinduced AMLs (Silver et al., 1999) . (1) MLP3, null for PU.1; (2) SA2 and (3) human Hela cell line used as a positive control. Western blotting was performed using standard laboratory protocols and the PU.1 protein detected using an antibody from BD Pharmingen (Oxford, UK)
Mutations of the PU.1 Ets domain N Suraweera et al summarized in Table 1 ). The transitions (C to T, C to A or G to A; Figure 1a) Western blot analysis of the myeloid leukaemia (ML) cell lines established from primary murine radiationinduced AMLs showing loss of one copy of chromosome 2 (Silver et al., 1999) , SA2 and KZ7 (R235S) and KZ8 (R235H), showed the presence of PU.1 protein (Figure 1b) . The detected protein matched the size predicted for PU.1 and, as expected, protein was absent in the Mlp3 line (null for the PU.1 gene). The expression of two interleukin cytokine family members (Il1b and Il3) and Csf2, all known to be transcriptional targets of PU.1, was investigated using Real-Time RT-QPCR analyses and Assay By Demand TaqMan probes (Applied Biosystems); all reactions were performed in triplicate and included Gapd as an endogenous control. A subsequent relative quantification study using the ABI SDS 2.1 software (Applied Biosystems) showed Il1b and Il3 to be expressed at low levels in the PU.1-null cell line Mlp3, but at four-and 64-fold higher levels in SA2 (R235S mutant in hemizygous state). No increased expression of another PU.1 target, Csf2, was found in SA2. While each line is likely to have acquired additional genetic changes that may influence cytokine expression, it is possible that some differential function by the R235S mutant protein may be retained; this requires further investigation.
A series of human tAMLs have also been investigated. No mutations of PU.1 were found in the coding regions, 5 0 UTR, the human/mouse-conserved portion of the 3 0 UTR, or the promoter region of any human secondary AMLs (n ¼ 24) from patients who had received therapy for a prior malignancy. We next considered the possibility of human/mouse-conserved regions upstream of PU.1 that might play a role in the regulation of this gene. Six highly conserved blocks (Ups1-6; Figure 2 ) were identified with the furthest conserved segment (Ups1) 17.1 kb upstream of the PU.1 promoter in humans and 14.5 kb in mice (Figure 2 ). Although the dispersed nature of these conserved blocks suggested an intron/exon arrangement, no expressed sequence tag or mRNA was identified to indicate a previously unidentified gene. The disruption of this region by introduction of a neomycin resistance cassette in mice had led to reduced PU.1 gene expression and AML (Rosenbauer et al., 2004) . A screen for sequence variants in the human tAMLs found no mutations. No polymorphisms were found in Ups1-4, but single-nucleotide polymorphisms were found in both Ups 5 and 6, adjacent to the PU.1 promoter (Figure 2) . A comparison to randomly selected normal human controls sequenced for Ups5 and 6 (n ¼ 57 and 61, respectively) indicated that the observed polymorphisms were not overrepresented in patients presenting with tAML (Table 2; P>0.4 and P>0.8, respectively; Fisher's exact test). PU.1 as a member of the ETS family of transcription factors is characterized by a highly conserved region of amino acids that form a winged (a þ b) helix-turn-helix motif, which binds DNA to facilitate promoter-specific transcriptional responses (Donaldson et al., 1994; Kodandapani et al., 1996; Pio et al., 1996; Jia et al., 1999 ; Figure 3 ). Located at the very carboxyl-terminal Figure 2 The upstream regions of PU.1 highly conserved in mouse and human. The relative position of the six regions in mouse and human are indicated. The overall level of conservation between man and mouse was B90%
Mutations of the PU.1 Ets domain N Suraweera et al part of the protein, this domain interacts with various proteins including GATA1 binding protein 1 (GATA1), CCAAT/enhancer binding protein beta (CEBPB), and other myeloid regulators such as c-jun and RUNX1/ AML-1 (Nagulapalli et al., 1995; Petrovick et al., 1998; Yamamoto et al., 1999) . The DNA-binding domain of PU.1 consists of three a helices and four b sheets, enclosing a hydrophobic core that bind to a DNA target with an invariant GGA core sequence, which is further augmented by the flanking nucleotides base pairs [(C/ A)GGA(A/T)(G/C)] . Two very highly conserved amino acids, R232 and R235, from the recognition a-3 helix have been shown to interact directly with the target DNA by binding to the core GGA sequence via both direct and water-mediated base-specific bonds ; Figure 3 ). In PU.1, unlike other Ets proteins, only a single hydrogen bond, rather than two, is formed between R235 and the first guanine of the recognition sequence (Mo et al., 1998) . Importantly, various site-directed mutagenesis studies have revealed that substitution of the R235 by any other amino acid completely abrogates DNA recognition . Hence, loss of R235 is known to ablate the DNA-binding function of the Ets domain, leading to loss of expression of downstream targets. However, mutation of R235 might not represent a null allele as some PU.1 interactions that are independent of this residue may well remain functionally intact. In radiation-induced murine AML, there was no apparent reduction of PU.1 expression with the sole exception of the Mlp3 cell line where two interstitial deletion events have resulted in complete loss of both gene copies (Silver et al., 1999) . The identification of circulating preleukaemic clones with deletion of one copy of chromosome 2 within a short time of radiation exposure (Breckon et al., 1991; Bouffler et al., 1997) and the relatively long latency period prior to AML presentation (B650 days) suggest an AML induction mechanism based on loss of one PU.1 copy, followed by a mutation specific to the highly conserved R235 residue, resulting in functional impairment of the Ets binding domain. Conversion of the R to a C, S or H occurs at high frequency in murine AMLs that have lost the other copy (Table 1) ; the retention of one apparently functional copy of PU.1 in a minority of AML suggests an alternative pathway of leukaemogenesis. Figure 3 The amino-acid sequence of the PU.1 Ets domain of human and mouse. Secondary structure features are indicated below the alignment: (a) Residues that are highly conserved are in grey; residues that are in the hydrophobic core are marked with an asterix; and residues that binds target DNA are marked with an arrow. The position of the three a helices and four b helices are also indicated. R235 is shown in large font and represents the site of mutagenesis observed in AML mouse. Genes that interact with specific helixes within the Ets domain of PU.1 are also shown. In addition to these, AML1, CD11c and IRF4 are also known to interact with the Ets domain, specific helixes of which are unknown. (b) Schematic representation of the hydrogen bonds (solid lines) and the van der Waal interactions (dashed lines) between the a3 helix of PU.1 and the target DNA containing the recognition sequence GGAA Mutations of the PU.1 Ets domain N Suraweera et al Overall, the mouse data indicate a highly specific mechanism of myeloid leukaemogenesis possibly driven by loss of one PU.1 copy. This event may itself be unique to the mouse and might relate to the radiationsensitive proximal and distal breakpoint cluster regions that have been identified and mapped on chromosome 2 (Clark et al., 1996; Silver et al., 1999; Finnon et al., 2002) . The juxtaposing of these fragile domains in time and space within the interphase nuclei of precursor bone marrow cells would be expected to promote site-specific postirradiation chromosomal interaction, leading to interstitial loss of a significant proportion of one copy of mouse chromosome 2 that includes the PU.1 locus (Silver et al., 1999) . The presence of genes important to the haematopoietic system (leucocyte tyrosine kinase, zinc-finger protein 106, erythrocyte protein band 4.2 and b-microglobulin) at the most distal of the cluster regions (Finnon et al., 2002) and their possible disruption as a consequence of domain-specific radiation fragility may have a major influence on the subsequent selection of the missense mutation at R235 of PU.1. In humans, these haematopoietic genes are positioned on 15q15.1-q22, while PU.1 is found on chromosome 11p11-12. LOH of this region on chromosome 11 is exceptionally rare in human AML reducing the chances of a first leukaemogenic step that parallels that seen in murine radiation-induced AML.
We have now shown that PU.1 mutation does not occur in a series of human tAMLs. Although we cannot exclude certain types of change such as large heterozygous deletions, no mutations were found in regions upstream of the human PU.1 promoter that are highly conserved between humans and mice, and may have a regulatory function. These data, and the failure to find mutation at the R235 residue in over 600 human AMLs (Lamandin et al., 2002; Mueller et al., 2002; Vegesna et al., 2002; Dohner et al., 2003; Ley et al., 2003; Mueller et al., 2003) , suggest that the leukaemogenic mechanism observed in the mouse are unique to this model system. However, it is possible that mutation of R235 may occur in those very few human AMLs that do show LOH of PU.1 (Mitelman et al., 1997) .
While biallelic mutation of human AML appears to be exceptionally rare (three possible cases out of over 600), reduction of PU.1 expression may play a role in ML. Although it has been shown that the AML1-ETO fusion gene product generated by the t(8;21) translocation inhibits PU.1 function (Vangala et al., 2003) , further work is needed to show if reduced PU.1 expression or impaired protein function does lead to human AML. It has been reported that mice carrying hypomorphic PU.1 (Sfpi1) alleles on chromosome 2 that reduce PU.1 expression to 20% of normal levels develop AML in a majority (97%; 33/34) of engineered mice (Rosenbauer et al., 2004) . The authors propose that graded reduction of PU.1 induces AML by promoting recurring chromosomal changes including trisomy of chromosome 15, creating further mutation and outgrowth of leukaemic cells. Similar to analysis of an earlier knockout PU.1 model , AML does not occur in PU.1 knockdown mice showing complete or 50% loss of PU.1 expression (Rosenbauer et al., 2004) . Although the study by Rosenbauer et al. (2004) has shown a direct link between AML and PU.1, the mechanism proposed remains open to some doubt as the Neo used to replace the -14 kb upstream regulatory region of PU.1 may effect the expression of genes several 100 kb away (Pham et al., 1996) . In the present study, mutations in the conserved, and potential regulatory regions, upstream of PU.1 were not found in human AML.
In summary, we have identified the cause of radiationinduced AML in a mouse model. Our data indicate that loss of one copy of PU.1 as a consequence of flanking radiation-sensitive fragile domains on mouse chromosome 2, and subsequent R235 conversion are highly specific to murine radiation-induced AMLs. This precise mechanism is unlikely to be observed in human AML. The data present here on AMLs induced following irradiation, in conjunction with results from PU.1 knockdown mice, indicate that reduction of PU.1 below critical functional or physiological levels causes AML in the mouse. In radiation-induced AMLs, this is a consequence of LOH and the R235 mutation, and in the knockdown mice through direct reduction in expression levels. In human, reduced levels of PU.1 may be critical to AML development, not through direct mutation but through genes that interact with PU.1. Hence, the search for mutation in genes that interact with PU.1 and thereby control its expression needs to continue. Furthermore, an in silico analysis of cDNAs indicates that the PU.1 gene in humans produces seven types of transcripts predicted to encode seven distinct proteins isoforms (www.ncbi.nlm.-nih.gov). This suggests that loss of particular variants may have a role in human leukaemogenesis and that a study of human AML cells for the absence of certain protein isoforms may prove informative.
